Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + tislelizumab + paclitaxel + nedaplatin
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
anlotinib + tislelizumab + paclitaxel + nedaplatin is a multi-modality combination regimen being evaluated as a neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC). This regimen integrates four distinct therapeutic approaches: anlotinib, a multi-target tyrosine kinase inhibitor that suppresses angiogenesis by targeting VEGFR, FGFR, PDGFR, and c-Kit; tislelizumab, a humanized IgG4 monoclonal antibody that inhibits the PD-1/PD-L1 pathway to enhance anti-tumor immune responses; and a chemotherapy doublet of paclitaxel (a microtubule stabilizer) and nedaplatin (a second-generation platinum-based DNA cross-linker). The combination aims to maximize tumor shrinkage and improve pathological complete response rates prior to surgical resection. Clinical investigation is primarily led by The First Affiliated Hospital of Guangxi Medical University.
- Brand names
- FukanghuaBaizeanJiebaishu
- Other names
- ANTP regimen
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + tislelizumab + paclitaxel + nedaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + tislelizumab + paclitaxel + nedaplatin.